HENDERA
831152
LINGOOD
833284
WANDA BEARING
920002
4
WUHAN LAND
830779
5
Hanjia Design Group
300746
US Stock MarketDetailed Quotes
GNPX Genprex
- 0.3800
- +0.0122+3.32%
Close Feb 26 16:00 ET
- 0.3792
- -0.0008-0.21%
Post 19:53 ET
3.23MMarket Cap-0.04P/E (TTM)
0.3903High0.3701Low295.18KVolume0.3796Open0.3678Pre Close112.36KTurnover3.48%Turnover RatioLossP/E (Static)8.51MShares5.410052wk High1.94P/B3.22MFloat Cap0.280652wk Low--Dividend TTM8.48MShs Float778.0000Historical High--Div YieldTTM5.48%Amplitude0.2800Historical Low0.3800Avg Price1Lot Size
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
Genprex Stock Forum
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
Benzinga· 1 min ago
Researching Novel Diabetes Gene Therapy Using Potentially Re-Dosable Non-Viral Delivery System
Strategic Collaboration with CDMO Partner Positions Genprex as a Thought-Leader in Diabetes Market
The announcement of Genprex's research into non-viral delivery systems for their diabetes gene therapy represents a potentially significant technological advancement in the field. The current standard AAV-based delivery systems, while effective, have a critical limitation: they can only be administered once due to immune response development. The exploration of lipid nanoparticle delivery systems could be a game-changer, particularly given their potent...
Can This New Delivery System Transform Diabetes Gene Therapy? Genprex's Latest Breakthrough
The consolidation of Genprex's license agreements with the University of Pittsburgh marks a important strategic advancement in their diabetes gene therapy program. The amended agreement creates an extensive IP portfolio covering multiple gene therapy combinations using Pdx1 and MafA transcription factors, significantly strengthening their competitive position in the $50+ billion diabetes treatment market.
The formation of Convergen Biot...
Genprex Inc - Signs New Exclusive License Agreement With University of Pittsburgh of Commonwealth System of Higher Education
Genprex Provides Update on Diabetes Gene Therapy Program
Tuesday, 18th February at 8:15 am
Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and
Type 2 Diabetes
Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development
AUSTIN, Texas, Feb. 18, 2025 /PRNewswire/ -- Genprex, Inc.("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-...
Revolutionary Diabetes Gene Therapy Breakthrough: Genprex Unveils Dual-Action Treatment Strategy
No comment yet